20-F/A: Aeterna Zentaris Inc. Files Amendment No. 1 to Form 20-F/A for Fiscal Year Ended December 31, 2022
Form 20-F/A Amendment
Aeterna Zentaris Inc. files an amendment to its annual report to correct the financial statement preparation standard reference from Item 17 to Item 18 of Form 20-F.
Summary
- Aeterna Zentaris Inc. has filed Amendment No. 1 to its Annual Report on Form 20-F/A for the fiscal year ended December 31, 2022.
- The amendment corrects an error in the original filing, specifying that the consolidated financial statements were prepared in accordance with Item 18, not Item 17, of Form 20-F.
- The consolidated financial statements remain unchanged, and all references to Item 17 in the original filing now refer to Item 18.
- The amendment includes the cover page, an explanatory note, and corrected Item 17 and Item 18.
- The document reaffirms that the information reflects the original filing date and does not account for events occurring after that date.
- As of December 31, 2022, the company had 4,855,876 common shares outstanding.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing amendment, indicating a neutral sentiment. The correction of an error suggests attention to detail and compliance.
Positives
- The amendment clarifies the financial reporting standard used, ensuring transparency.
- The company is current on its SEC filings.
Future Outlook
The document does not contain any forward-looking statements beyond the scope of the correction.
Industry Context
This is a routine regulatory filing amendment and does not significantly impact the broader industry context.
Key Dates
| Date | Description |
|---|---|
| 2018-01-16 | Aeterna Zentaris entered into a License Agreement with Strongbridge Ireland Limited. |
| 2018-07-23 | Strongbridge launched product sales of Macrilen (macimorelin) in the U.S. |
| 2018-12-19 | Strongbridge sold the entity which owned the License Agreement for the U.S. and Canadian rights to Macrilen (macimorelin) to Novo Nordisk. |
| 2019-05-08 | Shareholders re-approved the Companys shareholder rights plan. |
| 2020-02-21 | The Company closed a registered direct offering for 139,130 common shares. |
| 2020-06-16 | The Company registered the common shares underlying the September 2019 and February 2020 warrants. |
| 2020-07-07 | The Company closed a public offering of 1,066,667 units at a price of $11.25 per unit. |
| 2020-08-05 | The Company closed a securities purchase agreement of 497,115 common shares at a purchase price of $14.08 per common share. |
| 2020-09-14 | The Company registered the common shares underlying the August 2020 warrants. |
| 2020-11-16 | The Company entered into an amendment (the Novo Amendment) of its existing License Agreement with Novo Nordisk. |
| 2020-12-07 | The Company entered into an exclusive licensing agreement with Consilient Health Limited (CH) for the commercialization of macimorelin. |
| 2021-02-19 | The Company completed an underwritten public offering of 820,390 common shares at $36.25 per common share. |
| 2021-02-22 | The Underwriter exercised the Underwriter Option and received 123,058 common shares. |
| 2021-08-10 | The Company entered into a trademark maintenance and assignment option agreement with ARES Trading SA. |
| 2021-11-30 | The Company and NK Meditech Limited (NK) entered into a licensing agreement. |
| 2022-07-15 | The Companys shareholders and board of directors approved an amendment to the Companys articles of incorporation to effect a 1-for-25 share consolidation (reverse split). |
| 2022-07-21 | The share consolidation (reverse split) was affected. |
| 2022-08-26 | Novo provided the Company with a notice of termination of the Novo Amendment. |
| 2023-03-15 | Consilient Health entered into an assignment agreement to transfer the current licensing agreement to Atnahs Pharma UK Limited (Pharmanovia). |
| 2023-05-23 | Termination of Novo Amendment is effective. |
Keywords
Form 20-F/A, Amendment, Financial Statements, Aeterna Zentaris, Item 18, Item 17
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.